| [1] |
国家卫生健康委办公厅.新型冠状病毒感染的肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-18)[2020-02-19].http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm.
|
| [2] |
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019 [J]. N Engl J Med, 2020, 382(8): 727-733.
|
| [3] |
Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern [J]. Lancet, 2020, 395(10223):470-473.
|
| [4] |
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020, 395(10223):507-513.
|
| [5] |
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet,2020,395(10224):565-574.
|
| [6] |
Daniel Wrapp, Nianshuang Wang, Kizzmekia S, et al. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation[EB/OL].(2020-02-11)[2020-02-19]. doi: 10.1101/2020.02.11.944462.
|
| [7] |
张艳丽, 蒋澄宇. 细胞因子风暴:急性呼吸窘迫综合征中的主宰生命之手[J]. 生命科学, 2015, 27(5):554-557. ZHANG Yanli, JIANG Chengyu. Cytokine storm in ARDS[J]. Chinese Bulletin of Life Sciences, 2015, 27(5):554-557.
|
| [8] |
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020, 395(10223):497-506.
|
| [9] |
Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque[J]. J Virol, 2012, 86(11): 6055-6066.
|
| [10] |
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [J]. Lancet Respir Med, 2020. doi: 10.1016/S2213-2600(20)30076-X.
|
| [11] |
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease[J]. Nat Rev Immunol, 2008, 8(9):726-736.
|
| [12] |
Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways[J]. Ann N Y Acad Sci, 2015, 1351: 114-126. doi: 10.1111/nyas.12815.
|
| [13] |
Fu X, Liu G, Halim A, et al. Mesenchymal stem cell migration and tissue repair[J]. Cells, 2019, 8(8):784.
|
| [14] |
Qin ZH, Xu JF, Qu JM, et al. Intrapleural delivery of MSCs attenuates acute lung injury by paracrine/endocrine mechanism [J]. J Cell Mol Med, 2012, 16(11):2745-2753.
|
| [15] |
Curley GF, Hayes M, Ansari B, et al. Mesenchymal stem cells enhance recovery and repair following ventilatorinduced lung injury in the rat[J]. Thorax, 2012, 67(6):496-501.
|
| [16] |
Antunes MA, Abreu SC, Cruz FF, et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema[J]. Respir Res, 2014, 15: 118. doi: 10.1186/s12931-014-0118-x.
|
| [17] |
Antebi B, Mohammadipoor A, Batchinsky AI, et al. The promise of mesenchymal stem cell therapy for acute respiratory distress syndrome [J]. J Trauma Acute Care Surg, 2018, 84(1): 183-191.
|
| [18] |
Wu X, Dao Thi VL, Huang Y, et al. Intrinsic immunity shapes viral resistance of stem cells[J]. Cell, 2018, 172(3):423-438.
|
| [19] |
Sobacchi C, Palagano E, Villa A, et al. Soluble factors on stage to direct mesenchymal stem cells fate[J]. Front Bioeng Biotechnol, 2017, 5(32): 1-9.
|
| [20] |
Ethokic JM, Tomic SZ, Colic MJ. Cross-talk between mesenchymal stem/stromal cells and dendritic cells [J]. Curr Stem Cell Res Ther, 2016, 11(1): 51-65.
|
| [21] |
Wang G, Cao K, Liu K, et al. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells[J]. Cell Death Differ, 2018, 25(7):1209-1223.
|
| [22] |
Song Y, Dou H, Li X, et al. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of IL-1β-primed mesenchymal stem cells against sepsis: IL-1β enhances immunomodulatory effect of MSCs[J]. Stem Cells, 2017, 35(5): 1208-1221.
|
| [23] |
Li S, Wu H, Han D, et al. A novel mechanism of mesenchymal stromal cell-mediated protection against sepsis: restricting inflammasome activation in macrophages by increasing mitophagy and decreasing mitochondrial ROS[J]. Oxid Med Cell Longev, 2018, 4(13): 3537609-3537623.
|
| [24] |
Fayyad-Kazan H, Faour WH, Badran B, et al. The immunomodulatory properties of human bone marrowderived mesenchymal stromal cells are defined according to multiple immunobiological criteria [J]. Inflamm Res, 2016, 65(6): 501-510.
|
| [25] |
Zanotti L, Angioni R, Cali B, et al. Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1[J]. Leukemia, 2016, 30(5): 1143-1154.
|
| [26] |
Li B, Zhang H, Zeng M, et al. Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysaccharideinduced apoptosis partially by inhibiting the Wnt/β-catenin pathway[J]. Cell Biology International, 2015, 39(2): 192-200.
|
| [27] |
Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung [J]. Am J Respir Cell Mol Biol, 2005, 33(2): 145-152.
|
| [28] |
Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. Coli endotoxin-induced acute lung injury in the ex vivo perfused human lung [J]. Proc Natl Acad Sci USA, 2009, 106(38): 16357-16362.
|
| [29] |
Yang Y, Hu S, Xu X, et al. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo[J]. Mediators Inflamm, 2016, 2016:2347938.doi: 10.1155/2016/2347938.
|
| [30] |
LI QC, LIANG Y, SU ZB. Prophylactic treatment with MSC-derived exosomes attenuates traumatic acute lung injury in rats[J]. Am J Physiol Lung Cell Mol Physiol, 2019, 316(6):1107-1117.
|
| [31] |
Loy H, Kuok DIT, Hui KPY, et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A(H5N1)virusassociated acute lung injury [J]. J Infect Dis, 2019, 219(2):186-196.
|
| [32] |
Zhang X, Gao F, Li Q, et al. MSCs with ACE II gene affect apoptosis pathway of acute lung injury induced by bleomycin[J]. Exp Lung Res, 2015, 41(1):32-43.
|
| [33] |
Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem(stromal)cells for treatment of ARDS: a phase 1 clinical trial [J]. Lancet Respir Med, 2015, 3(1): 24-32.
|
| [34] |
Ahn SY, Chang YS, Kim JH, et al. Two-Year Follow-Up Outcomes of Premature Infants Enrolled in the Phase I Trial of Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia [J]. J Pediatr, 2017, 185(1):49-54.
|
